1887

Abstract

The aim of this study was to investigate the reliability of disc diffusion testing with penicillin, erythromycin and ciprofloxacin within the viridans group streptococci (VGS). In total, the antibiotic susceptibilities of 167 VGS isolates were compared by standard disc diffusion and broth microdilution methods, and these phenotypic data were compared to the carriage of the respective gene resistance determinants [ and (macrolides); QRDR, , , and (quinolones)]. Overall, there were 35 discrepancies [resistant by MIC and susceptible by zone diameter (21.0 %)] between MIC and disc diameter when penicillin susceptibility was interpreted by Clinical and Laboratory Standards Institute criteria. Scattergrams showed a bimodal distribution between non-susceptible and susceptible strains when erythromycin susceptibility was tested by both methods. Thirty-four (20.4 %) isolates were categorized as resistant by MIC breakpoints, while disc diameter defined these as having intermediate resistance. With ciprofloxacin, three isolates (1.8 %) showed minor discrepancies between MIC breakpoints and disc diameter. Isolates non-susceptible to all three antimicrobial agents tested were reliably distinguished from susceptible isolates by disc diffusion testing, except for the detection of low-level resistance to penicillin, where broth microdilution or an alternative quantitative MIC method should be used. Otherwise, we conclude that disc diffusion testing is a reliable method to detect strains of VGS non-susceptible to penicillin, erythromycin and ciprofloxacin, as demonstrated with their concordance to their gene resistance characteristics.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.027573-0
2011-12-01
2020-01-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/12/1782.html?itemId=/content/journal/jmm/10.1099/jmm.0.027573-0&mimeType=html&fmt=ahah

References

  1. Baddour L. M., Wilson W. R., Bayer A. S., Fowler V. G. Jr, Bolger A. F., Levison M. E., Ferrieri P., Gerber M. A., Tani L. Y. et al. & other authors ( 2005;). Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. . Circulation 111:, e394–e434. [CrossRef][PubMed]
    [Google Scholar]
  2. Bruckner L., Gigliotti F.. ( 2006;). Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance. . Semin Pediatr Infect Dis 17:, 153–160. [CrossRef][PubMed]
    [Google Scholar]
  3. Cerdá Zolezzi P., Rubio Calvo M. C., Millán L., Goñi P., Canales M., Capilla S., Durán E., Gómez-Lus R.. ( 2004;). Macrolide resistance phenotypes of commensal viridans group streptococci and Gemella spp. and PCR detection of resistance genes. . Int J Antimicrob Agents 23:, 582–589. [CrossRef][PubMed]
    [Google Scholar]
  4. CLSI ( 2005;). Performance Standards for Antimicrobial Susceptibility Testing, document M100–S15. . Wayne, PA:: Clinical and Laboratory Standards Institute;.
  5. Edson D. C., Glick T., Massey L. D.. ( 2006;). Susceptibility testing practices for Streptococcus pneumoniae: results of a proficiency testing survey of clinical laboratories. . Diagn Microbiol Infect Dis 55:, 225–230. [CrossRef][PubMed]
    [Google Scholar]
  6. Han X. Y., Kamana M., Rolston K. V.. ( 2006;). Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. . J Clin Microbiol 44:, 160–165. [CrossRef][PubMed]
    [Google Scholar]
  7. Jumbe N. L., Louie A., Miller M. H., Liu W., Deziel M. R., Tam V. H., Bachhawat R., Drusano G. L.. ( 2006;). Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. . Antimicrob Agents Chemother 50:, 310–317. [CrossRef][PubMed]
    [Google Scholar]
  8. Kerr K. G., Armitage H. T., McWhinney P. H.. ( 1999;). Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy. . Support Care Cancer 7:, 28–30. [CrossRef][PubMed]
    [Google Scholar]
  9. Lindgren M., Jalava J., Rantakokko-Jalava K., Meurman O.. ( 2007;). In vitro susceptibility of viridans group streptococci isolated from blood in southwest Finland in 1993–2004. . Scand J Infect Dis 39:, 508–513. [CrossRef][PubMed]
    [Google Scholar]
  10. Maeda Y., Murayama M., Goldsmith C. E., Coulter W. A., Mason C., Millar B. C., Dooley J. S. G., Lowery C. J., Matsuda M. et al. & other authors ( 2011;). Molecular characterization and phylogenetic analysis of quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC and parE gene loci in viridans group streptococci isolated from adult patients with cystic fibrosis. . J Antimicrob Chemother 66:, 476–486. [CrossRef][PubMed]
    [Google Scholar]
  11. Marrer E., Schad K., Satoh A. T., Page M. G., Johnson M. M., Piddock L. J.. ( 2006;). Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae. . Antimicrob Agents Chemother 50:, 685–693. [CrossRef][PubMed]
    [Google Scholar]
  12. NCCLS ( 1994;). Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters, approved standard M23-A. . Wayne, PA:: National Committee for Clinical Laboratory Standards;.
  13. Razonable R. R., Litzow M. R., Khaliq Y., Piper K. E., Rouse M. S., Patel R.. ( 2002;). Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. . Clin Infect Dis 34:, 1469–1474. [CrossRef][PubMed]
    [Google Scholar]
  14. Schurek K. N., Adam H. J., Hoban D. J., Zhanel G. G.. ( 2006;). Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae. . Int J Antimicrob Agents 28:, 266–269. [CrossRef][PubMed]
    [Google Scholar]
  15. Tazumi A., Maeda Y., Goldsmith C. E., Coulter W. A., Mason C., Millar B. C., McCalmont M., Rendall J., Elborn J. S. et al. & other authors ( 2009;). Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF). . J Antimicrob Chemother 64:, 501–506. [CrossRef][PubMed]
    [Google Scholar]
  16. Tenover F. C., Mohammed M. J., Stelling J., O’Brien T., Williams R.. ( 2001;). Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization’s external quality assurance system for antimicrobial susceptibility testing. . J Clin Microbiol 39:, 241–250. [CrossRef][PubMed]
    [Google Scholar]
  17. Uh Y., Shin D. H., Jang I. H., Hwang G. Y., Lee M. K., Yoon K. J., Kim H. Y.. ( 2004;). Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from blood cultures in Korea. . J Antimicrob Chemother 53:, 1095–1097. [CrossRef][PubMed]
    [Google Scholar]
  18. Westling K., Julander I., Ljungman P., Jalal S., Nord C. E., Wretlind B.. ( 2006;). Viridans group streptococci in blood culture isolates in a Swedish university hospital: antibiotic susceptibility and identification of erythromycin resistance genes. . Int J Antimicrob Agents 28:, 292–296. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.027573-0
Loading
/content/journal/jmm/10.1099/jmm.0.027573-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error